Patents Assigned to MedImmune Limited
  • Patent number: 12209099
    Abstract: A compound of formula IV: as well as drug-linkers and conjugates comprising this compound, and the use of the conjugates in treating cancer.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: January 28, 2025
    Assignee: MEDIMMUNE LIMITED
    Inventors: Philip Wilson Howard, Thais Cailleau
  • Patent number: 12209126
    Abstract: The present invention relates to the use of NKG2A-neutralizing agents and PD-1 neutralizing agents to treat cancers, notable cancers that are not characterized by DNA mismatch repair deficiency. Provided are methods of treatment of a cancer, as well as compositions and kits useful for treating a cancer that is not characterized by DNA mismatch repair deficiency.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: January 28, 2025
    Assignees: MEDIMMUNE LIMITED, INNATE PHARMA
    Inventors: Shaad Essa Abdullah, Ashok Kumar Gupta, Xuyang Song
  • Patent number: 12187788
    Abstract: The present invention relates to methods for treating atopic dermatitis and related disorders in a subject using an interleukin-13 (IL-13) binding protein, such as an anti-IL-13 antibody or an IL-13-binding fragment thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: January 7, 2025
    Assignee: MedImmune Limited
    Inventors: Gene Colice, Rene van der Merwe, Paul Baverel
  • Patent number: 12187774
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: July 1, 2023
    Date of Patent: January 7, 2025
    Assignee: MEDIMMUNE LIMITED
    Inventors: Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
  • Patent number: 12178911
    Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.
    Type: Grant
    Filed: November 9, 2022
    Date of Patent: December 31, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'sa, Saba Ghazvini
  • Patent number: 12173050
    Abstract: This application provides antibodies and functional equivalents thereof which are capable of specifically binding RSV, as well as means and methods for producing them.
    Type: Grant
    Filed: April 18, 2023
    Date of Patent: December 24, 2024
    Assignee: MedImmune Limited
    Inventors: Nancy Ulbrandt, Nicole Kallewaard-Lelay, Andy Q. Yuan, Bettina Richter
  • Patent number: 12121590
    Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.
    Type: Grant
    Filed: June 6, 2023
    Date of Patent: October 22, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Patent number: 12110336
    Abstract: The present disclosure provides antibodies and antigen-binding fragments capable of binding PrPC. The disclosure further provides methods for making and using the antibodies and antigen-binding fragments.
    Type: Grant
    Filed: September 14, 2020
    Date of Patent: October 8, 2024
    Assignee: MedImmune Limited
    Inventors: Matthew Gardener, Jayne Hammersley, Maria Groves, Gareth Rees, Sadhana Podichetty, Andrew Billinton
  • Patent number: 12098191
    Abstract: Antibody for human amyloid beta. Antibody selectively binds human amyloid beta 42 peptide over human amyloid beta 40 peptide. Antibodies specific for amyloid beta 42 as therapeutic agents for binding amyloid beta 42 peptide and treating conditions associated with amyloidosis, such as Alzheimer's disease.
    Type: Grant
    Filed: February 16, 2022
    Date of Patent: September 24, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Maria Groves, Suzanne Gustavsson, Kina Höglund, Chris Lloyd, Adrian Nickson, Camilla Niva, Sylvia Simon, David Lowne, Fraser Welsh, Per-Ola Freskgard
  • Patent number: 12076406
    Abstract: In some embodiments, the disclosure provides for a conjugate comprising: a) a peptide that competes with an Fc fragment of an IgG for binding to an Fc receptor; and b) a targeting moiety that targets molecular aggregates. In some embodiments, the disclosure provides for methods of using the conjugates for treating a disease or disorder associated with aggregate formation.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: September 3, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Damian C. Crowther, Maria Herva, Roland Bürli, Lutz Jermutus
  • Patent number: 12024553
    Abstract: In one aspect, this disclosure describes methods of treating or preventing RSV infection in a patient in need thereof. The methods include dosing regiments for administering a composition including a fixed dose of an anti-RSV monoclonal antibody or an antigen binding fragment thereof. In another aspect, this disclosure describes pharmaceutical compositions for the treatment or prevention of RSV infection. In yet another aspect, this disclosure describes a pharmaceutical unit dose including nirsevimab.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: July 2, 2024
    Assignees: MedImmune Limited, Sanofi Pasteur Inc.
    Inventors: Anis Ahmed Khan, Vadryn Pierre
  • Patent number: 11938192
    Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: March 26, 2024
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
    Inventors: Jay Marshall Feingold, David Rodney Ungar
  • Patent number: 11904053
    Abstract: The present technology relates generally to dry powder formulations of antibodies specific for thymic stromal lymphopoietin (TSLP), as well as methods of treating asthma, using the dry powder formulations, suitably via pulmonary delivery.
    Type: Grant
    Filed: October 27, 2020
    Date of Patent: February 20, 2024
    Assignee: MEDIMMUNE LIMITED
    Inventors: Catherine Eugenie Chaillan Huntington, Susan Hoe, Prakash Manikwar, Roland Wilhelm Kolbeck, Emma Suzanne Cohen, David Lechuga-Ballesteros, Kellisa Beth Hansen, Dexter Joseph D'Sa, Saba Ghazvini
  • Patent number: 11897949
    Abstract: This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF? antagonist. The NGF antagonist and the TNF? antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF? antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF? antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF? antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF? antagonist administered alone.
    Type: Grant
    Filed: May 28, 2021
    Date of Patent: February 13, 2024
    Assignee: MedImmune Limited
    Inventors: Darren Schofield, Matthew Alexander Sleeman, Iain Patrick Chessell, Jonathan Hatcher, David Lowe
  • Patent number: 11845782
    Abstract: The present invention relates to Relaxin fusion polypeptides, in particular to Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: December 19, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Weidong Hao, Andrew Garcia, Changshou Gao, Isabelle Sermadiras
  • Patent number: 11834473
    Abstract: The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides may be produced in mammalian cells to present natural or un-natural O-glycan structures through metabolic labelling.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: December 5, 2023
    Assignee: MedImmune Limited
    Inventors: Adam Tibbles, Monika Papworth, Daniel Higazi, Emmanuel Rossy, Katarzyna Anna Kozakowska, Thomas Vincent Murray
  • Patent number: 11813335
    Abstract: A conjugate of formula (I): Ab-(DL)p??(I) wherein: Ab is an antibody that binds to AXL; DL is
    Type: Grant
    Filed: September 24, 2021
    Date of Patent: November 14, 2023
    Assignees: MEDIMMUNE LIMITED, ADC THERAPEUTICS SA
    Inventor: Patricius Hendrikus Cornelis Van Berkel
  • Patent number: 11795205
    Abstract: The present invention relates to heterodimeric Relaxin fusion polypeptides, in particular to heterodimeric Relaxin 2 fusion polypeptides and uses thereof. Thus, the invention provides Relaxin fusion polypeptides, nucleic acid molecules, vectors, host cells, pharmaceutical compositions and kits comprising the same and uses of the same including methods of treatment. The polypeptides and compositions of the invention may be useful, in particular, in the treatment of cardiovascular diseases, for example for the treatment of heart failure.
    Type: Grant
    Filed: June 16, 2021
    Date of Patent: October 24, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Isabelle Sermadiras, Monika Anna Papworth, Judy Christiane Paterson, Esther Marie Martin, Peng Ke
  • Patent number: 11795225
    Abstract: The present invention relates to binding molecules (e.g. antibodies) for the treatment of cancer, and related antibody-drug conjugates.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: October 24, 2023
    Assignee: MedImmune Limited
    Inventors: Krista Lynne Kinneer, Gareth Charles Davies, David Gareth Rees, Jennifer Louise Percival-Alwyn, John Edward Andrews, Jon Chesebrough
  • Patent number: 11779650
    Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.
    Type: Grant
    Filed: August 19, 2020
    Date of Patent: October 10, 2023
    Assignee: MEDIMMUNE LIMITED
    Inventors: Patricius Hendrikus Cornelis Van Berkel, Philip Wilson Howard